An update on the complex relationship between clozapine and pneumonia

References

• de Leon J, Ruan CJ, Schoretsanitis G, et al. A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology. Psychother Psychosom. 2020;89(4):200–214.
   PubMed Web of Science ®Google Scholar
• Spina E, Hiemke C, de Leon J. Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2016;12(4):407–422.
   PubMed Web of Science ®Google Scholar
• Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the food and drug administration, 1998-2005. Arch Intern Med. 2007;167:1752–1759. .
   PubMed Web of Science ®Google Scholar
• De Leon J, Sanz EJ, De Las Cuevas C. Data from the world health organization’s pharmacovigilance database supports the prominent role of pneumonia in mortality associated with clozapine adverse drug reactions. Schizophr Bull. 2020;46(1):1–3.
   PubMed Web of Science ®Google Scholar
• Cicala G, Barbieri MA, Spina E, et al., A comprehensive review of swallowing difficulties and dysphagia associated with antipsychotics in adults. Expert Rev Clin Pharmacol. 2019;12(3):219–234.
   PubMed Web of Science ®Google Scholar
• de Leon J, Ruan CJ, Verdoux H, et al. Clozapine is strongly associated with the risk of pneumonia and inflammation. Gen Psychiatr. 2020;33(2):e100183.
   PubMed Web of Science ®Google Scholar
• de Leon J, Sanz EJ, Norén GN, et al. Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics. World Psychiatry. 2020;19(1):120–121.
   PubMed Web of Science ®Google Scholar
• Rohde C, Siskind D, de Leon J, et al., Antipsychotic medication exposure, clozapine, and pneumonia: results from a self-controlled study. Acta Psychiatr Scand. 2020;142(2):78–86.
   PubMed Web of Science ®Google Scholar
• Villasante-Tezanos AG, Rohde C, Nielsen J, et al., Pneumonia risk: approximately one-third is due to clozapine and two-thirds is due to treatment-resistant schizophrenia. Acta Psychiatr Scand. 2020;142(1):66–67.
   PubMed Web of Science ®Google Scholar
• Chou FH, Tsai KY, Chou YM. The incidence and all-cause mortality of pneumonia in patients with schizophrenia: a nine-year follow-up study. J Psychiatr Res. 2013;47(4):460–466.
   PubMed Web of Science ®Google Scholar
• de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76(2–3):135–157.
   PubMed Web of Science ®Google Scholar
• Baskaran V, Murray RL, Hunter A, et al. Effect of tobacco smoking on the risk of developing community acquired pneumonia: A systematic review and meta-analysis. PLoS One. 2019;14(7):e0220204.
   PubMed Web of Science ®Google Scholar
• Langmore SE, Terpenning MS, Schork A, et al. Predictors of aspiration pneumonia: how important is dysphagia? Dysphagia. 1998;13(2):69–81.
   PubMed Web of Science ®Google Scholar
• Haga T, Ito K, Sakashita K, et al. Risk factors for pneumonia in patients with schizophrenia. Neuropsychopharmacol Rep. 2018;38(4):204–209.
   PubMedGoogle Scholar
• Cheng SY, Chen WY, Liu HC, et al. Benzodiazepine and risk of pneumonia in schizophrenia: a nationwide case-control study. Psychopharmacology (Berl). 2018;235(11):3329–3338.
   PubMed Web of Science ®Google Scholar
• Wu CS, Chen TY, Tsai SY, et al. Estimating the risk of pneumonia in patients with schizophrenia newly receiving clozapine: a nationwide cohort study. J Clin Psychopharmacol. 2019;39(4):297–304.
   PubMed Web of Science ®Google Scholar
• Phung DT, Wang Z, Rutherford S, et al. Body mass index and risk of pneumonia: a systematic review and meta-analysis. Obes Rev. 2013;14(10):839–857.
   PubMed Web of Science ®Google Scholar
• Correll CU, Brevig T, Brain C. Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists. BMC Psychiatry. 2019;19(1):362.
   PubMed Web of Science ®Google Scholar
• Bachmann CJ, Aagaard L, Bernardo M, et al. International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand. 2017;136(1):37–51.
   PubMed Web of Science ®Google Scholar
• de Leon J, Diaz FJ, Josiassen RC, et al. Weight gain during a double-blind multidosage clozapine study. J Clin Psychopharmacol. 2007;27(1):22–27.
   PubMed Web of Science ®Google Scholar
• Diaz FJ, Josiassen RC, de Leon J. The effect of body weight changes on total plasma clozapine concentrations determined by applying a statistical model to the data from a double-blind trial. J Clin Psychopharmacol. 2018;38(5):442–446.
   PubMed Web of Science ®Google Scholar
• Knol W, van Marum RJ, Jansen PA, et al. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc. 2008;56(4):661–666.
   PubMed Web of Science ®Google Scholar
• Kuo CJ, Yang SY, Liao YT, et al. Second-generation antipsychotic medications and risk of pneumonia in schizophrenia. Schizophr Bull. 2013;39(3):648–657.
   PubMed Web of Science ®Google Scholar
• Ruan CJ, Zang YN, Cheng YH, et al., Around 3% of 1,300 levels were elevated during infections in a retrospective review of 131 Beijing hospital in-patients with more than 24,000 days of clozapine treatment. Psychother Psychosom. 2020;89(4):255–257.
   PubMed Web of Science ®Google Scholar
• Schoretsanitis G, Kuzin M, Kane JM, et al. Elevated clozapine concentrations in clozapine-treated patients with hypersalivation. Clin Pharmacokinetics. 2020 Oct 1. Online ahead of print. DOI:10.1007/s40262-020-00944-5.
   PubMed Web of Science ®Google Scholar
• de Leon J. Atypical antipsychotic dosing: the effect of smoking and caffeine. Psychiatr Serv. 2004;55(5):491–493.
   PubMed Web of Science ®Google Scholar
• Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther. 2004;76(2):178–184.
   PubMed Web of Science ®Google Scholar
• Liao YT, Yang SY, Liu HC, et al. Cardiac complications associated with short-term mortality in schizophrenia patients hospitalized for pneumonia: a nationwide case-control study. PLoS One. 2013;8(7):e70142.
   PubMed Web of Science ®Google Scholar
• Rohde C, Polcwiartek C, Kragholm K, et al. Adverse cardiac events in out-patients initiating clozapine treatment: a nationwide register-based study. Acta Psychiatr Scand. 2018;137(1):47–53.
   PubMed Web of Science ®Google Scholar
• Siskind D, Sidhu A, Cross J, et al. Systematic review and meta-analysis of rates of clozapine-associated myocarditis and cardiomyopathy. Aust N Z J Psychiatry. 2020;54:467–481.
   PubMed Web of Science ®Google Scholar
• Verdoux H, Quiles C, de Leon J. Clinical determinants of fever in clozapine users and implications for treatment management: A narrative review. Schizophr Res. 2019;211:1–9. .
   PubMed Web of Science ®Google Scholar